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The liver is a vital organ responsible for maintaining nutrient homeostasis. After a meal,
insulin stimulates glycogen and lipid synthesis in the liver; in the fasted state, glucagon
induces gluconeogenesis and ketogenesis, which produce glucose and ketone bodies for
other tissues to use as energy sources.These metabolic changes involve spatiotemporally
co-ordinated signaling cascades. O-linked β-N -acetylglucosamine (O-GlcNAc) modification
has been recognized as a nutrient sensor and regulatory molecular switch. This review
highlights mechanistic insights into spatiotemporal regulation of liver metabolism by O-
GlcNAc modification and discusses its pathophysiological implications in insulin resistance,
non-alcoholic fatty liver disease, and fibrosis.
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INTRODUCTION
The liver is the second largest organ and accounts for about 2% of
the body mass of an adult human being. It is a major metabolic
organ responsible for maintaining whole-body homeostasis in a
changing nutritional environment. Dysregulation of liver metab-
olism is associated with a wide range of chronic liver disorders.
LIVER METABOLISM DURING THE FEEDING/FASTING CYCLE
The liver plays a key role in maintaining normal glucose levels
between meals. When blood glucose is in excess (e.g., after a meal),
the liver rapidly takes up glucose to produce glycogen (glyco-
genesis). When blood glucose levels fall below a normal range
(72–85 mg/dL for healthy individuals), glycogen is broken down
into glucose (glycogenolysis), which is then exported to the blood-
stream. If the glycogen reserve is exhausted, the liver will generate
glucose from non-carbohydrate carbon substrates, such as lactate,
pyruvate, glycerol, and glucogenic amino acids (gluconeogenesis).
The liver also oxidizes triglycerides to produce energy dur-
ing fasting. When carbohydrates and proteins are in excess, they
are converted into fatty acids and triglycerides in the liver, and
these are then exported and stored in adipose tissue. The liver
is also responsible for producing lipoproteins, cholesterol, and
phospholipids.
The metabolic function of the liver during the feeding/fasting
cycle is tightly regulated by several endocrine hormones, par-
ticularly insulin and glucagon. Insulin enhances glucose uptake
in muscle and adipose tissue and inhibits glucose production in
the liver, thereby regulating blood glucose concentration. Insulin
also stimulates the synthesis of fatty acids, glycogen, and pro-
teins. The opposing effects are largely mediated by glucagon – it
raises blood glucose concentration by promoting glycogenolysis
and gluconeogenesis. These signaling and biochemical pathways
can be regulated by insulin and glucagon at the transcriptional,
translational, and post-translational levels.
INSULIN RESISTANCE AND NAFLD
Since the liver is a vital organ to sustain metabolic homeostasis,
chronic liver disorders are among the most devastating human
diseases. Liver dysfunction can be a consequence of infection,
immune disorders, alcohol- or drug-induced liver damage. It
can contribute to a constellation of common metabolic disor-
ders, including insulin resistance, non-alcoholic fatty liver disease
(NAFLD), and non-alcoholic steatohepatitis (NASH).
Hepatic insulin resistance causes impaired glycogen synthesis
and failure to suppress glucose production, eventually resulting in
hyperglycemia. Insulin resistance is often associated with increased
lipogenesis and hepatic steatosis (fatty liver).
Non-alcoholic fatty liver disease is now the most common
liver disorder in the US, where 30% of the general adult popu-
lation suffers from the disease (1). NAFLD can be characterized
by excessive lipid accumulation in hepatocytes. In addition, a
strong correlation between NAFLD and type 2 diabetes (T2D)
has been reported: 70–80% of T2D and obesity patients have
NAFLD and most patients with NAFLD have hepatic insulin
resistance (2).
The majority of patients with NAFLD starts with simple steato-
sis and is often asymptomatic. However, a subset of NAFLD
patients with simple steatosis can progress to NASH with mani-
festations of inflammation, hepatocellular injury, and fibrosis (3).
Patients with fibrosis tend to have poor prognosis, often progress-
ing to cirrhosis and even hepatocellular cancer (4). However, the
molecular basis for the development of NAFLD and NASH is not
clearly understood.
O-GlcNAc MODIFICATION
O-GlcNAcylation has emerged as an important regulatory mech-
anism underlying normal liver physiology and liver diseases. This
post-translational modification uses UDP-GlcNAc as the substrate
for the attachment of the acetylglucosamine (GlcNAc) moiety to
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the hydroxyl groups of serine and threonine residues of proteins
(5, 6). Since UDP-GlcNAc is synthesized via the hexosamine
biosynthesis pathway (HBP), which involves nutrients such as glu-
cose, free fatty acids, uridine, and glutamine, O-GlcNAcylation
can serve as a nutrient sensor, tuning various cellular processes
in response to systemic metabolic status (7–9). The cycling of
O-GlcNAcylation is controlled by two highly conserved enzymes:
O-GlcNAc transferase (OGT) catalyzes the addition of O-GlcNAc
to proteins and O-GlcNAcase (OGA) catalyzes the removal of the
monosaccharide (10–12). This dynamic modification is prevalent
on signaling proteins, transcription factors, metabolic enzymes,
and histones and has emerged as a key regulator of diverse cellu-
lar processes, including signal transduction, gene expression, and
protein degradation (7, 13–17).
This review focuses on the spatiotemporal regulation of
key signaling pathways in glucose and lipid metabolism by O-
GlcNAcylation. Understanding the regulatory role of this modi-
fication provides significant insight into normal liver physiology
and liver disease processes.
O-GlcNAc IN NORMAL LIVER METABOLISM
O-GlcNAc REGULATION OF FEEDING RESPONSE
Insulin plays a central role in glucose and lipid metabolism. After
a meal, a sizable amount of insulin is rapidly released from the
pancreas and is circulated to critical organs such as skeletal muscle,
adipose tissue, and liver. In the liver, insulin induces acute activa-
tion of the insulin signaling cascade (acute postprandial response)
followed by the attenuation of this pathway (prolonged postpran-
dial response) (18). The temporal patterns of signal transduction
are largely dictated by dynamic protein phosphorylation (19, 20).
Similar to protein phosphorylation, O-GlcNAc modification can
influence protein function by regulating protein–protein interac-
tion, protein stability, nuclear-cytoplasmic shuttling, and intrinsic
protein activity (21). The interplay between phosphorylation and
O-GlcNAcylation has been implicated in the regulation of critical
cellular processes. Here, we review the known effects of O-GlcNAc
modification on insulin signal transduction in acute and pro-
longed postprandial responses, focusing on the role of O-GlcNAc
in attenuating insulin signaling (Figure 1).
FIGURE 1 | Spatiotemporal regulation of feeding response by
O-GlcNAcylation. (Left) Acute postprandial response. During early insulin
signaling, OGT remains in the cytosol. Insulin binds to insulin receptor (IR)
and triggers its autophosphorylation. Phosphorylation of IR recruits IRS1 to be
phosphorylated, after which IRS1 binds to PI3K. PI3K catalyzes the production
of PIP3, which recruits PDK1 to be phosphorylated and activated. Activated
PDK1 phosphorylates and activates AKT, which further phosphorylates and
activated downstream targets, including GSK3β and FOXO, which enhances
glycogen synthesis and suppresses gluconeogenesis. (Right) Prolonged
postprandial response. The insulin signaling pathway needs to be attenuated
after a period of stimulation in order to maintain homeostasis.
O-GlcNAcylation of insulin signal proteins contributes to the attenuation of
the pathway. During prolonged insulin signaling, OGT translocates to the
plasma membrane and binds with PIP3 through the PIP3-binding domain.
OGT is then phosphorylated and activated by IR. Activated OGT
O-GlcNAcylates key insulin signaling proteins including IRS1, PI3K, PDK1, and
AKT, antagonizing the activation by phosphorylation on these proteins. These
events lead to decreased glycogen synthesis and increased gluconeogenesis.
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Acute postprandial response
In acute postprandial response, insulin binds to the insulin recep-
tor (IR) and triggers the autophosphorylation of various tyrosine
residues within the intracellular tyrosine kinase domain of the
IR. This leads to the recruitment and phosphorylation of down-
stream proteins, including insulin receptor substrate (IRS). Sub-
sequently, IRS binds and phosphorylates phosphatidylinositol-3-
kinase (PI3K), which mediates a variety of critical signaling events.
PI3K catalyzes the formation of membrane phosphatidylinositol
3,4,5-bisphosphate (PIP3), which recruits AKT to be activated by
3-phosphoinositide-dependent protein kinase 1 (PDK1) through
phosphorylation at threonine 308. AKT then phosphorylates sev-
eral target proteins, including glycogen synthase kinase (GSK3),
AS160, and forkhead box protein O (FOXO). In glycogen synthe-
sis, AKT phosphorylates and deactivates GSK3 (22), the enzyme
responsible for phosphorylating and deactivating glycogen syn-
thase. This leads to increased glycogen synthesis. In gluconeogene-
sis, phosphorylation of FOXO by AKT triggers FOXO export from
the nucleus, thereby preventing FOXO from promoting gluco-
neogenic gene transcription (23). Thus, in acute insulin response,
sequential phosphorylation events lead to increased glycogen
synthesis and decreased gluconeogenic gene expression (Figure 1).
Prolonged postprandial response
The precise control of the duration of signal transduction is crit-
ical for maintaining physiological homeostasis. For instance, at
some point after acute activation, insulin signal transduction is
dampened through several feedback mechanisms (18). First, pro-
tein tyrosine phosphatases, such as PTP1B, have been shown to act
as negative regulators of insulin signaling through dephosphoryla-
tion of IR (24). Lipid phosphatases, specifically PTEN and SHIP2,
can dampen the PI3K pathway both in vitro and in vivo (25). Sec-
ond, phosphorylation of specific Ser/Thr sites on IRS by protein
kinases such as ribosomal protein S6 kinase beta-1 (S6K1) termi-
nates insulin signaling (26,27). Third, recent studies have indicated
that O-GlcNAcylation plays a profound role in attenuating insulin
signaling (28, 29).
In response to prolonged insulin stimulation, OGT translo-
cates from the cytoplasm to the plasma membrane through the
C-terminal PIP3-binding domain (28), leading to phosphoryla-
tion and activation of OGT by IR (30). Active OGT is known
to O-GlcNAcylate and deactivate key insulin signaling proteins,
including IRS-1, PI3K, PDK1, and AKT, thereby facilitating insulin
signal attenuation (29, 30) (Figure 1).
Insulin receptor substrate deactivation is an important mecha-
nism for terminating insulin signaling. IRS-1 is a direct substrate
of OGT (29). Increased O-GlcNAcylation of IRS-1 in 3T3-L1
adipocytes reduces IRS-1 interaction with PI3K p85 and Tyr phos-
phorylation of IRS-1 at the Tyr 608 and increases IRS-1 phospho-
rylation at Ser 307 and Ser 632/635 (29). PI3K and PDK1 are also
direct substrates of OGT and are implicated in insulin signaling
attenuation (28).
Decreased AKT activity is essential for insulin signal termina-
tion. Increased O-GlcNAcylation of AKT at Thr 305/312 decreases
AKT activity by reducing Thr 308 phosphorylation, which disrupts
AKT/PDK1 interaction. In contrast, Ser 473 phosphorylation is
unaffected (31).
Decreased AKT activity also reduces glycogen synthesis by
decreasing phosphorylation of GSK3β. GSK3β is known to be
modified by O-GlcNAcylation, and the inhibition of GSK3β by
lithium alters global O-GlcNAc levels (32). However, the func-
tion of GSK3β O-GlcNAcylation has not yet been elucidated.
Furthermore, O-GlcNAcylation of glycogen synthase itself is
responsive to high glucose or glucosamine treatment and reduces
the activity of the enzyme (33).
Lipogenesis in feeding response
Hepatic de novo lipogenesis allows for the conversion of glucose
into fatty acids during feeding. Recent evidence indicates that glu-
cose flux promotes lipogenesis through O-GlcNAcylation. The
role of O-GlcNAcylation in both activating lipogenesis and atten-
uating insulin signaling raises an interesting question regarding
the temporal regulation of insulin signaling. However, the stud-
ies on O-GlcNAcylation of lipogenic proteins have not addressed
the dynamics of this modification in relation to the temporal
regulation of lipogenesis.
The liver X receptors (LXRs) have long been viewed as nutrient
sensors for lipid metabolism, glucose homeostasis, and inflam-
mation. LXRs have been found to be O-GlcNAcylated in human
Huh7 cells (34). High glucose increases LXR O-GlcNAcylation
and transcriptional activity on the promoter of the sterol regu-
latory element-binding protein 1c (SREBP-1c), the master tran-
scriptional regulator of hepatic lipogenesis (34). In vivo studies
have shown that increased hepatic LXR O-GlcNAcylation can be
observed in refed mice and in streptozotocin-induced diabetic
mice (34).
The carbohydrate-responsive element-binding protein (ChRE
BP) plays a significant role in glycolysis and lipogenesis. In
HEK293T cells and hepatocytes, O-GlcNAcylation of ChREBP
has been shown to stabilize the protein and to increase its
transcriptional activity on lipogenic genes (35).
O-GlcNAc REGULATION OF FASTING RESPONSE
During fasting, energy metabolism shifts from glucose utiliza-
tion to fat burning. In the liver, fasting induces glycogenoly-
sis and gluconeogenesis in order to fuel glycolytic tissues, such
as the brain and red blood cells. In short-term fasting, gluco-
neogenesis is mainly induced by glucagon through the cyclic
AMP-CREB pathway. During a period of prolonged fasting,
hepatic gluconeogenesis has shown to be sustained through
the peroxisome proliferator-activated receptor γ co-activator 1α
(PGC-1α)-dependent mechanisms (36).
Short-term fasting
During short-term fasting, glucagon stimulates gluconeogenesis
by enhancing the activity of the cyclic AMP-responsive element-
binding protein (CREB). CREB is phosphorylated at Ser 133 by
cAMP-dependent Ser/Thr kinase protein kinase A (PKA) (37).
Phosphorylation of CREB increases its interaction with CBP/p300
(38–40), which has been shown to promote gluconeogenic gene
expression by acetylating nucleosomal histones (41–44). CREB
directly enhances the expression of pyruvate carboxylase (PC),
phosphoenolpyruvate carboxykinase 1 (PEPCK1), and glucose-
6-phosphatase (G6PC) genes upon its binding to cAMP response
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elements (CREs). Phosphorylated CREB also promotes the expres-
sion of peroxisome proliferator-activated receptor-γ co-activator
1α (PGC1α), which is a critical co-activator for prolonged
stimulation of gluconeogenic gene transcription (45).
O-GlcNAcylation of many gluconeogenic transcription fac-
tors and cofactors has been reported to promote glucose pro-
duction in the liver. OGT can induce hepatic gluconeogenesis
by O-GlcNAcylation of CRTC2, the co-activator of CREB. At
basal levels, CRTCs are phosphorylated at Ser 70 and Ser 171
by salt-inducible kinases (SIKs) and other members of the AMP-
activated protein kinase (AMPK) family and are sequestered in the
cytoplasm by 14-3-3 proteins (46). In response to cAMP and cal-
cium signals, CRTC2 is dephosphorylated and O-GlcNAcylated
at the same site. This promotes CRTC2 translocation into the
nucleus and binding to CREB, which induce gluconeogenesis (47)
(Figure 2).
Prolonged fasting
During prolonged fasting, OGT primarily affects PGC1α-
mediated expression of gluconeogenic genes. PGC1α acts as a
co-activator for the glucocorticoid receptor, the hepatocyte nuclear
factor 4 (HNF4), and FOXO1, which further stimulates the expres-
sion of gluconeogenic genes (45). OGT can target PGC-1α via host
cell factor C1 (HCF-1) (8). O-GlcNAcylation stabilizes PGC-1α by
recruiting BAP1 for de-ubiquitination (8). PGC-1α helps recruit
OGT to O-GlcNAcylate and activate FOXO1 (48), which further
promotes hepatic glucose production (Figure 2). Our previous
work also demonstrates that OGT can physically and functionally
interact with the glucocorticoid receptor. It is, therefore, plau-
sible that OGT is also involved in glucocorticoid induction of
gluconeogenesis (49).
In the above sections, we have provided a snapshot view of
the molecular events regulated by O-GlcNAcylation in the differ-
ent phases of the feeding/fasting cycle. It should be noted that
these phases are not strictly divided but exist on the contin-
uum of time. The feeding and fasting responses are directed by
precise spatiotemporal regulation of insulin signaling cascades.
Despite remarkable advances in our understanding of the role
of O-GlcNAcylation in insulin signaling, how O-GlcNAcylation
crosstalks with phosphorylation is not well known. Exploring the
mechanistic and kinetic features of O-GlcNAcylation on key sig-
naling proteins holds great promise for a better understanding of
normal liver metabolism.
O-GlcNAc IN LIVER DISEASES
Non-alcoholic fatty liver disease is now the leading cause of liver
disease in the US. NAFLD refers to a wide spectrum of liver dis-
orders from simple steatosis (fatty liver) to NASH. One of the
earliest features of NAFLD is accumulation of lipids in hepa-
tocytes. A proportion of patients progress to NASH, which is
characterized by ballooned hepatocytes, inflammatory infiltrate
and fibrosis in the liver. Fatty liver disease is reported to be strongly
associated with insulin resistance. Hepatic insulin resistance has a
major impact on whole-body energy metabolism. Recent studies
on O-GlcNAcylation shed light on the etiology of hepatic insulin
resistance, fatty liver, and associated fibrosis.
O-GlcNAc AND HEPATIC INSULIN RESISTANCE
The liver is an insulin-sensitive organ critical for the mainte-
nance of nutrient homeostasis. Hepatic insulin resistance pro-
duces derangements in liver metabolism such as uncontrolled
glucose production, impaired glycogen synthesis, and enhanced
FIGURE 2 | Spatiotemporal regulation of fasting response by
O-GlcNAcylation. (Left) During short-term fasting, glucagon stimulates
gluconeogenesis by enhancing the activity of CREB. Phosphorylation of
CREB by PKA directly promotes gluconeogenic gene expression.
Additionally, OGT can induce gluconeogenesis by O-GlcNAcylating
CRTC2, the co-activator of CREB. When CRTC2 is dephosphorylated and
then O-GlcNAcylated at the same site, it translocates into the nucleus
and binds to CREB to induce gluconeogenesis. (Right) In prolonged
fasting, OGT targets PGC-1α via a complex with HCF-1. Both PGC-1α and
HCF-1 can be O-GlcNAcylated. O-GlcNAcylated PGC-1α helps recruit
OGT to glycosylate and activate FOXO1, which further promotes hepatic
glucose production.
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lipogenesis. In the development of hepatic insulin resistance,
O-GlcNAcylation is associated with various changes in gluco-
neogenesis, glycogenesis, and glycolysis. As discussed above, O-
GlcNAcylation has been identified as a negative regulator of
insulin signal transduction. Hepatic overexpression of OGT in
mice impairs the expression of insulin-responsive genes and causes
insulin resistance and dyslipidaemia (28, 50) (Figure 3).
Uncontrolled gluconeogenesis is one of the hallmarks of dia-
betic liver and contributes to hyperglycemia. O-GlcNAcylation
has been found on many gluconeogenic transcription factors and
cofactors, including CRTC2, HCF-1, PGC-1α, and FOXO1. Global
O-GlcNAcylation levels have been shown to be elevated in the liver
of high fat diet-fed and db/db mice. Hepatic overexpression of
OGA in these mice decreases O-GlcNAcylation of CRTC2, down-
regulates gluconeogenic gene expression, and attenuates hyper-
glycemia (47). OGT O-GlcNAcylates and activates FOXO1 during
prolonged fasting to stimulate gluconeogenesis. The levels of HCF-
1 are elevated in the liver of high fat diet-fed and db/db mice, which
is causally linked with uncontrolled gluconeogenesis and hyper-
glycemia. Consistently, knockdown of OGT and HCF-1 restores
glucose homeostasis in db/db mice (8).
The liver undergoes glycogenesis to absorb excessive blood glu-
cose. Glycogen synthase is activated when insulin signaling turns
on and inhibits GSK3β. Activation of glycogen synthase is often
suppressed in insulin resistance. High glucose has been shown to
enhance O-GlcNAcylation of glycogen synthase, which is associ-
ated with reduced enzymatic activity in a cell culture model (33).
This finding suggests that O-GlcNAcylation of glycogen synthase
impairs glycogenesis and exacerbates hyperglycemia. This might
produce a vicious cycle between hepatic insulin resistance and
O-GlcNAcylation.
Recent studies also indicate that O-GlcNAcylation modulates
glycolysis by inhibiting phosphofructokinase 1 (PFK1) activity and
redirecting glucose flux into the pentose phosphate pathway (PPP)
(17). Overexpression of OGT or pharmacological inhibition of
OGA in many cell lines leads to increased global O-GlcNAcylation,
decreased glycolysis, and decreased ATP concentration. Further
studies should clarify whether O-GlcNAcylation inhibits glycoly-
sis in the liver and whether this contributes to the pathogenesis of
insulin resistance.
O-GlcNAc AND NAFLD
Non-alcoholic fatty liver disease is characterized by triglyceride
accumulation in the cytoplasm of hepatocytes, arising from an
imbalance between lipid acquisition and removal. Insulin insen-
sitivity presumably leads to suppressed lipogenesis, which may
alleviate NAFLD symptoms. However, diabetic animals often have
“selective insulin resistance,” where insulin fails to suppress gluco-
neogenesis but retains its ability to activate lipogenesis (51). The
conundrum of selective insulin resistance has not been resolved.
It is also under debate whether selective insulin resistance and
NAFLD are inherently related to each other.
The role of O-GlcNAcylation in regulating lipogenesis might
hold the key to this paradox because O-GlcNAcylation sup-
presses insulin signaling but activates lipogenic pathways. O-
GlcNAcylation increases ChREBP protein level and transcriptional
activity on lipogenic genes (35). Importantly, ChREBP is hyper-
O-GlcNAcylated in the liver of db/db mice. OGA overexpres-
sion reduces ChREBP glycosylation and protects these mice from
hepatic steatosis. Another paradox involves farnesoid X receptor
(FXR), a nuclear receptor that inhibits expression of SREBP1c
and LXRα (52). Patients with NAFLD have lower levels of FXR
mRNA and protein (53). An independent study has demonstrated
that high glucose concentrations, which are believed to be a com-
mon pathophysiological condition in NAFLD patients, increases
FXR O-GlcNAcylation and enhances FXR gene expression and
protein stability (54). More direct evidence is required to reveal
how O-GlcNAcylation affects NAFLD progression through FXR
(Figure 3).
O-GlcNAc AND LIVER FIBROSIS
As NAFLD progresses to NASH, fibrosis becomes one of the com-
mon features among NASH patients and often correlates with poor
prognosis. Fibrosis is characterized by excessive deposition of the
extracellular matrix and can be regarded as a scarring process of
the liver in response to repeated injury. NASH patients with liver
fibrosis are more susceptible to cirrhosis (4), which is believed to
be more irreversible than fibrosis. Therefore, fibrosis serves as a
valuable therapeutic target to retard the progression of NASH. To
date, the evidence that links O-GlcNAcylation to fibrosis is still
limited but does shed some light on the topic.
FIGURE 3 | O-GlcNAc regulation of liver disease. Aberrant
hepatic O-GlcNAcylation leads to hyperglycemia by attenuating
insulin signaling, activating gluconeogenesis, and suppressing
glycogen synthesis. O-GlcNAcylation may contribute to NAFLD by
stimulating de novo lipogenesis. O-GlcNAcylation may also play a
role in the initiation and the progress of fibrosis by activating
HSCs. Key targets of O-GlcNAcylation involved in related
pathways are listed.
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Activated hepatic stellate cells (HSCs) are the major source of
the extracellular matrix in the liver (55). It was reported that ele-
vated levels of O-GlcNAcylation are essential for HSC activation
and upregulation of collagen expression in vitro (56). Both in vitro
and in vivo studies confirm that FXR activation limits the transdif-
ferentiation of HSCs from a resting, fat-storing phenotype toward
a myofibroblast-like phenotype (57, 58). Given their effects on
lowering inflammatory and fibrogenic processes, a number of syn-
thetic FXR agonists are being used to treat different hepatic and
metabolic disorders (59, 60). Nevertheless, the role of FXR O-
GlcNAcylation in the context of fibrosis has not been elucidated.
FOXO, which can be O-GlcNAcylated, also has a potential role in
fibrosis. A study showed that HSC transdifferentiation was sup-
pressed by FOXO1 (61). Paradoxically, enhanced FOXO1 expres-
sion and nuclear localization were reported in NASH patients (62).
Further study is required to address whether O-GlcNAcylation of
FOXO1 plays a role in liver fibrosis (Figure 3).
CONCLUSION
It is becoming clear that protein O-GlcNAcylation is critical for
metabolic control in time and space. In hepatocytes, cytosolic O-
GlcNAc is crucially involved in resetting insulin signaling, whereas
nuclear O-GlcNAc has a key role in transcriptional regulation
of gluconeogenesis and lipogenesis. This regulatory mechanism
may serve as a “rheostat” that ensures the fluctuation of circulat-
ing nutrients within a limited range during the feeding/fasting
cycle. Under pathophysiological conditions such as overnutri-
tion or stress, aberrant cellular O-GlcNAcylation leads to exces-
sive glucose production and lipid accumulation in the liver. As
such, O-GlcNAc disturbance is likely a unifying cause of hyper-
glycemia, fatty liver, and fibrosis. Small molecules that target
O-GlcNAc signaling should be explored to treat these medical
conditions.
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